SEARCH

SEARCH BY CITATION

References

  • Basi G. S., Hemphill S., Brigham E. F. et al. (2010) Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer’s disease. Alzheimers Res. Ther. 2, 36.
  • Beher D., Fricker M., Nadin A. et al. (2003) In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. Biochemistry 42, 81338142.
  • Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I. and Shearman M. S. (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 4341943426.
  • Bihel F., Das C., Bowman M. J. and Wolfe M. S. (2004) Discovery of a subnanomolar helical D-tridecapeptide inhibitor of γ-secretase. J. Med. Chem. 47, 39313933.
  • Citron M., Diehl T. S., Gordon G., Biere A. L., Seubert P. and Selkoe D. J. (1996) Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc. Natl. Acad. Sci. USA 93, 1317013175.
  • Das C., Berezovska O., Diehl T. S., Genet C., Buldyrev I., Tsai J. Y., Hyman B. T. and Wolfe M. S. (2003) Designed helical peptides inhibit an intramembrane protease. J. Am. Chem. Soc. 125, 1179411795.
  • De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K. and Van Leuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387390.
  • Dovey H. F., John V., Anderson J. P. et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173181.
  • Eriksen J. L., Sagi S. A., Smith T. E. et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440449.
  • Esler W. P., Kimberly W. T., Ostaszewski B. L. et al. (2000) Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell Biol. 2, 428434.
  • Esler W. P., Das C., Campbell W. A. et al. (2002a) Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase. Nat. Cell Biol. 4, E110111.
  • Esler W. P., Kimberly W. T., Ostaszewski B. L., Ye W., Diehl T. S., Selkoe D. J. and Wolfe M. S. (2002b) Activity-dependent isolation of the presenilin/γ-secretase complex reveals nicastrin and a γ substrate. Proc. Natl. Acad. Sci. USA 99, 27202725.
  • Esler W. P., Das C. and Wolfe M. S. (2004) Probing pockets S2-S4’ of the gamma-secretase active site with (hydroxyethyl)urea peptidomimetics. Bioorg. Med. Chem. Lett. 14, 19351938.
  • Fleisher A. S., Raman R., Siemers E. R. et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 10311038.
  • Fraering P. C., Ye W., Strub J. M. et al. (2004) Purification and characterization of the human gamma–secretase complex. Biochemistry 43, 97749789.
  • Fraering P. C., Ye W., Lavoie M. J., Ostaszewski B. L., Selkoe D. J. and Wolfe M. S. (2005) gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide binding site. J. Biol. Chem. 280, 4198741996.
  • Funamoto S., Morishima-Kawashima M., Tanimura Y., Hirotani N., Saido T. C. and Ihara Y. (2004) Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry 43, 1353213540.
  • Fuwa H., Takahashi Y., Konno Y. et al. (2007) Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. ACS Chem. Biol. 2, 408418.
  • Ghosh A. K., Gemma S. and Tang J. (2008) beta-Secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics 5, 399408.
  • Gillman K. W., Starrett J. E., Parker M. F. et al. (2010) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med. Chem. Lett. 1, 120124.
  • Goedert M. and Spillantini M. G. (2006) A century of Alzheimer’s disease. Science 314, 777781.
  • Green R. C., Schneider L. S., Amato D. A., Beelen A. P., Wilcock G., Swabb E. A. and Zavitz K. H. (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 25572564.
  • Haapasalo A. and Kovacs D. M. (2011) The many substrates of presenilin/gamma-secretase. J. Alzheimers Dis. 25, 328.
  • He G., Luo W., Li P. et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease. Nature 467, 9598.
  • Herreman A., Hartmann D., Annaert W. et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc. Natl. Acad. Sci. USA 96, 1187211877.
  • Higaki J., Quon D., Zhong Z. and Cordell B. (1995) Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651659.
  • Hyde L. A., McHugh N. A., Chen J. et al. (2006) Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-di hydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J. Pharmacol. Exp. Ther. 319, 11331143.
  • Imamura Y., Watanabe N., Umezawa N., Iwatsubo T., Kato N., Tomita T. and Higuchi T. (2009) Inhibition of gamma-secretase activity by helical beta-peptide foldamers. J. Am. Chem. Soc. 131, 73537359.
  • Imbimbo B. P., Del Giudice E., Colavito D. et al. (2007) 1-(3′,4′-Dichloro-2-fluoro[1,1’-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822830.
  • Imbimbo B. P., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M. and Windisch M. (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease. Br. J. Pharmacol. 156, 982993.
  • Imbimbo B. P., Giardino L., Sivilia S. et al. (2010) CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer’s disease. J. Alzheimers Dis. 20, 159173.
  • Kimberly W. T., LaVoie M. J., Ostaszewski B. L., Ye W., Wolfe M. S. and Selkoe D. J. (2003) γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proc. Natl. Acad. Sci. USA 100, 63826387.
  • Klafki H. W., Paganetti P. A., Sommer B. and Staufenbiel M. (1995) Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation. Neurosci. Lett. 201, 2932.
  • Klafki H., Abramowski D., Swoboda R., Paganetti P. A. and Staufenbiel M. (1996) The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J. Biol. Chem. 271, 2865528659.
  • Kopan R. and Ilagan M. X. (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216233.
  • Kornilova A. Y., Bihel F., Das C. and Wolfe M. S. (2005) The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc. Natl. Acad. Sci. USA 102, 32303235.
  • Kounnas M. Z., Danks A. M., Cheng S. et al. (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. Neuron 67, 769780.
  • Kreft A., Harrison B., Aschmies S. et al. (2008) Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg. Med. Chem. Lett. 18, 42324236.
  • Kreft A. F., Martone R. and Porte A. (2009) Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer’s disease. J. Med. Chem. 52, 61696188.
  • Kukar T., Prescott S., Eriksen J. L., Holloway V., Murphy M. P., Koo E. H., Golde T. E. and Nicolle M. M. (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8, 54.
  • Kukar T. L., Ladd T. B., Bann M. A. et al. (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925929.
  • Lanz T. A., Wood K. M., Richter K. E. et al. (2010) Pharmacodynamics and pharmacokinetics of the {gamma}-secretase inhibitor, PF-3084014. J. Pharmacol. Exp. Ther. 334, 269277.
  • Li Y. M., Lai M. T., Xu M. et al. (2000a) Presenilin 1 is linked with gamma -secretase activity in the detergent solubilized state. Proc. Natl. Acad. Sci. USA 97, 61386143.
  • Li Y. M., Xu M., Lai M. T. et al. (2000b) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689694.
  • Martone R. L., Zhou H., Atchison K. et al. (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer’s disease. J. Pharmacol. Exp. Ther. 331, 598608.
  • May P., Altsteil L., Bender M. et al. (2002) Chronic treatment with a functional gamma-secretase inhibitor reduces Abeta burden and plaque pathology in PDAPP mice. Neurobiol. Aging 23, S133.
  • Mayer S. C., Kreft A. F., Harrison B. et al. (2008) Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer’s disease. J. Med. Chem. 51, 73487351.
  • Morohashi Y., Kan T., Tominari Y. et al. (2006) C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J. Biol. Chem. 281, 1467014676.
  • Netzer W. J., Dou F., Cai D. et al. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl. Acad. Sci. USA 100, 1244412449.
  • Peretto I., Radaelli S., Parini C. et al. (2005) Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J. Med. Chem. 48, 57055720.
  • Petit A., Bihel F., Alves da Costa C., Pourquie O., Checler F. and Kraus J. L. (2001) New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat. Cell Biol. 3, 507511.
  • Pissarnitski D. (2007) Advances in gamma-secretase modulation. Curr. Opin. Drug Discov. Dev. 10, 392402.
  • Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y. et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25, 436445.
  • Saito T., Suemoto T., Brouwers N. et al. (2011) Potent amyloidogenicity and pathogenicity of Abeta43. Nat. Neurosci. 2011, 2858.
  • Sato T., Dohmae N., Qi Y. et al. (2003) Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J. Biol. Chem. 278, 2429424301; E-pub 22003 Apr 24221.
  • Sato T., Nyborg A. C., Iwata N., Diehl T. S., Saido T. C., Golde T. E. and Wolfe M. S. (2006) Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry 45, 86498656.
  • Searfoss G. H., Jordan W. H., Calligaro D. O. et al. (2003) Adipsin: a biomarker of gastrointestinal toxicity mediated by a functional gamma secretase inhibitor. J. Biol. Chem. 278, 4610746116.
  • Seiffert D., Bradley J. D., Rominger C. M. et al. (2000) Presenilin-1 and -2 are molecular targets for gamma -secretase inhibitors. J. Biol. Chem. 275, 3408634091.
  • Shearman M. S., Beher D., Clarke E. E. et al. (2000) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 39, 86988704.
  • Shen J., Bronson R. T., Chen D. F., Xia W., Selkoe D. J. and Tonegawa S. (1997) Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89, 629639.
  • Siemers E., Skinner M., Dean R. A., Gonzales C., Satterwhite J., Farlow M., Ness D. and May P. C. (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126132.
  • Siemers E. R., Dean R. A., Friedrich S., Ferguson-Sells L., Gonzales C., Farlow M. R. and May P. C. (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol. 30, 317325.
  • Stanton M. G., Hubbs J., Sloman D. et al. (2009) Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 755758.
  • Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S. and Ihara Y. (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 1304213052.
  • Tanzi R. E. and Bertram L. (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120, 545555.
  • Van Broeck B., Chen J. M., Treton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M. and Rowley A. (2011) Chronic treatment with a novel gamma-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer’s disease. Br. J. Pharmacol. 163, 375389.
  • Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212216.
  • Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Ozols V., Fauq A., Golde T. E. and Koo E. H. (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 278, 3183131837.
  • Wolfe M. S. (2006) The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45, 79317939.
  • Wolfe M. S. (2008) Inhibition and modulation of gamma-secretase for Alzheimer’s disease. Neurotherapeutics 5, 391398.
  • Wolfe M. S., Citron M., Diehl T. S., Xia W., Donkor I. O. and Selkoe D. J. (1998) A substrate-based difluoro ketone selectively inhibits Alzheimer’s γ-secretase activity. J. Med. Chem. 41, 69.
  • Wolfe M. S., Xia W., Moore C. L., Leatherwood D. D., Ostaszewski B., Donkor I. O. and Selkoe D. J. (1999) Peptidomimetic probes and molecular modeling suggest Alzheimer’s γ-secretases are intramembrane-cleaving aspartyl proteases. Biochemistry 38, 47204727.
  • Wong P. C., Zheng H., Chen H. et al. (1997) Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387, 288292.
  • Wong G. T., Manfra D., Poulet F. M. et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 1287612882.
  • Yan X. X., Li T., Rominger C. M., Prakash S. R., Wong P. C., Olson R. E., Zaczek R. and Li Y. W. (2004) Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. J. Neurosci. 24, 29422952.
  • Zhao B., Yu M., Neitzel M. et al. (2008) Identification of gamma-secretase inhibitor potency determinants on presenilin. J. Biol. Chem. 283, 29272938.